Table 4 Cox multivariate analysis of the survival in recurrent breast cancer by breast cancer subgroup
| Â | HR-positive/HER-2-negative | HR-positive/HER-2-positive | HR-negative/HER-2-positive | HR-negative/HER-2-negative | ||||
|---|---|---|---|---|---|---|---|---|
| Â | HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P |
Age (>50 vs ≤50) | 1.21 (0.85-1.73) | 0.19 | 0.27 (0.11-0.70) | 0.006 | 1.32 (0.47-3.73) | 0.60 | 0.70 (0.44-1.13) | 0.14 |
T stage (T3,4 vs T1,2) | 2.00 (1.33-3.02) | 0.001 | 2.74 (1.08-6.92) | 0.03 | 1.40 (0.61-3.20) | 0.42 | 1.22 (0.74-2.00) | 0.44 |
No. of axillary nodes involved (3 < nodes vs ≤3 nodes) | 1.18 (0.77-1.79) | 0.45 | 0.93 (0.38-2.29) | 0.88 | 2.42 (0.99-5.89) | 0.054 | 1.52 (0.99-2.34) | 0.057 |
HR status (positive vs negative) | NA | NA | NA | NA | NA | NA | NA | NA |
HER-2 status (positive vs negative) | NA | NA | NA | NA | NA | NA | NA | NA |
Adjuvant endocrine therapy (yes vs no) | 1.01 (0.64-1.59) | 0.98 | 0.72 (0.29-1.77) | 0.47 | NA | NA | NA | NA |
Adjuvant chemotherapy (yes vs no) | 1.50 (1.03-2.19) | 0.04 | 1.69 (0.70-4.08) | 0.24 | 1.76 (0.68-4.53) | 0.24 | 0.74 (0.40-1.36) | 0.33 |
Relapse free interval (>2 yr vs ≤ 2 yr) | 1.00 (0.67-1.50) | 0.98 | 0.64 (0.30-1.37) | 0.25 | 0.26 (0.11-0.61) | 0.002 | 0.91 (0.55-1.52) | 0.73 |
Site of first recurrence (visceral vs non visceral) | 1.67 (1.17-2.39) | 0.005 | 2.95 (1.36-6.41) | 0.006 | 1.81 (0.77-4.27) | 0.18 | 1.77 (1.12-2.79) | 0.01 |
Brain metastatasis at diagnosis (yes vs no) | 2.22 (0.68-7.27) | 0.19 | 0.58 (0.06-5.33) | 0.63 | 6.02 (1.87-19.3) | 0.003 | 2.76 (0.97-7.83) | 0.056 |
AIs and/or trastuzumab for recurrent disease (yes vs no) | 0.37 (0.25-0.53) | <0.001 | 0.55 (0.10-2.96) | 0.49 | 0.61 (0.18-2.05) | 0.42 | NA | NA |
Time period (cohort B vs cohort A) | 0.81 (0.50-1.30) | 0.38 | 0.39 (0.19-0.79) | 0.009 | 0.12 (0.05-0.29) | <0.001 | 0.80 (0.50-1.29) | 0.36 |